Day One Biopharmaceuticals (DAWN)
(Delayed Data from NSDQ)
$16.48 USD
+1.56 (10.46%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $16.49 +0.01 (0.06%) 7:20 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
DAWN 16.48 +1.56(10.46%)
Will DAWN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DAWN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DAWN
Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More
Here's What Could Help Day One Biopharmaceuticals, Inc. (DAWN) Maintain Its Recent Price Strength
DAWN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Day One Biopharmaceuticals, Inc. (DAWN) Could Surge 85%: Read This Before Placing a Bet
Biotech ETF Tops in June: 5 Stocks That Outperform
Other News for DAWN
JPMorgan biotech analysts to hold an analyst/industry conference call
Analysts Are Bullish on These Healthcare Stocks: Accolade (ACCD), PROCEPT BioRobotics (PRCT)
Day One Biopharmaceuticals (DAWN) Shares Cross Below 200 DMA
Day One comments from call weighing on sentiment, says BofA
Xoma earns $9M milestone as FDA grants approval of Day One's NDA for OJEMDA